Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672451 · ClinicalTrials.gov registry record · Phase 2
Rhubarb and Angiotensin Converting Enzyme Inhibitor
A Phase 2 study, sponsored by Wake Forest University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00672451 is a Phase 2 study that was terminated before completion, run by Wake Forest University. The registered enrollment target is 8 participants.
The verdict
NCT00672451, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of this study is to determine the combined effect of rhubarb plus enalapril (an ACEI)in slowing the rate of decline of CKD in people with kidney disease from diabetes.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT rhubarb extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00672451
The ClinicalTrials.gov registry entry for NCT00672451 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00672451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00672451 about?
NCT00672451 is a clinical study titled "Rhubarb and Angiotensin Converting Enzyme Inhibitor". Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of t...
What is the current status of trial NCT00672451?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00672451?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), rhubarb extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00672451?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.